CKM Antikörper (full length)

Produktnummer ABIN7878037

Der Maus Monoklonal anti-CKM Antikörper (Klon CKMM-3341) (ABIN7878037) detektiert spezifisch CKM in WB und IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für CKM Antikörper (full length) (ABIN7878037)

Target: CKM (Creatine Kinase, Muscle (CKM))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CKM Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: CKMM-3341

Produktdetails anti-CKM Antikörper

Bindungsspezifität: full length

Verwendungszweck: Creatine Kinase M Antibody / CKM (azide and preservative free)

Aufreinigung: Protein G affinity chromatography

Immunogen: Recombinant full-length CKM protein was used as the immunogen for the Creatine Kinase M antibody.

Isotyp: IgG2a, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Creatine Kinase M antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the Creatine Kinase M antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu CKM

Target: CKM (Creatine Kinase, Muscle (CKM))

Andere Bezeichnung: Creatine Kinase M

Hintergrund: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31 % overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

UniProt: P06732